We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Sarepta Therapeutics (SRPT - Free Report) shares soared 35% in the last trading session to close at $23.77. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.5% loss over the past four weeks.
Sarepta Therapeutics’ stock rallied on positive investor sentiment following early clinical data from two of its siRNA programs, SRP-1001 for facioscapulohumeral muscular dystrophy type I and SRP-1003 for myotonic dystrophy type I. The studies showed dose-dependent muscle delivery, early biomarker activity, and favorable safety profiles. These findings support the potential of the αvβ6 integrin-targeted siRNA platform to improve muscle delivery and overcome key limitations of RNA therapies, reinforcing its promise to transform treatment for these rare genetic disorders.
This biopharmaceutical company is expected to post quarterly earnings of $0.80 per share in its upcoming report, which represents a year-over-year change of +123.4%. Revenues are expected to be $461.22 million, down 38.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Sarepta Therapeutics, the consensus EPS estimate for the quarter has been revised 9.8% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SRPT going forward to see if this recent jump can turn into more strength down the road.
Sarepta Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Caribou Biosciences, Inc. (CRBU - Free Report) , another stock in the same industry, closed the last trading session 3.3% higher at $1.88. CRBU has returned -15% in the past month.
Caribou Biosciences' consensus EPS estimate for the upcoming report has changed +7.6% over the past month to -$0.33. Compared to the company's year-ago EPS, this represents a change of +23.3%. Caribou Biosciences currently boasts a Zacks Rank of #2 (Buy).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT - Free Report) shares soared 35% in the last trading session to close at $23.77. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.5% loss over the past four weeks.
Sarepta Therapeutics’ stock rallied on positive investor sentiment following early clinical data from two of its siRNA programs, SRP-1001 for facioscapulohumeral muscular dystrophy type I and SRP-1003 for myotonic dystrophy type I. The studies showed dose-dependent muscle delivery, early biomarker activity, and favorable safety profiles. These findings support the potential of the αvβ6 integrin-targeted siRNA platform to improve muscle delivery and overcome key limitations of RNA therapies, reinforcing its promise to transform treatment for these rare genetic disorders.
This biopharmaceutical company is expected to post quarterly earnings of $0.80 per share in its upcoming report, which represents a year-over-year change of +123.4%. Revenues are expected to be $461.22 million, down 38.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Sarepta Therapeutics, the consensus EPS estimate for the quarter has been revised 9.8% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SRPT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Sarepta Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Caribou Biosciences, Inc. (CRBU - Free Report) , another stock in the same industry, closed the last trading session 3.3% higher at $1.88. CRBU has returned -15% in the past month.
Caribou Biosciences' consensus EPS estimate for the upcoming report has changed +7.6% over the past month to -$0.33. Compared to the company's year-ago EPS, this represents a change of +23.3%. Caribou Biosciences currently boasts a Zacks Rank of #2 (Buy).